Transpact Enterprises P/B Ratio
Current P/B Ratio
17.13
High Valuation
Very High - Significant premium, high growth expectations or speculative
Transpact Enterprises (TRANSPACT) P/B ratio is 17.13 (High), book value per share ₹ vs Healthcare average P/B of -0.33 — Very High - Significant premium, high growth expectations or speculative. Compare with TRANSPACT fair price to assess whether the stock is under or overvalued.
Current Valuation Metrics
P/B Ratio
17.13
Current Price
₹
Book Value/Share
₹
Exchange
None
Valuation Signal
Signal
Overvalued
Sector Context
Sector Average
-0.33
Sector Median
0.63
Sector Rank
#11 of 50
Sector Percentile
22.0%
TRANSPACT P/B Ratio — Valuation Insights & Book Value Analysis
Transpact Enterprises price-to-book ratio interpretation, valuation status and historical context — current P/B 17.13 (High). For live price, earnings yield and the full fundamental profile, see TRANSPACT screener.
- Stock appears overvalued with PB of 17.13, trading at significant premium to book value
- Trading at high premium to book value - indicates strong growth expectations or asset-light business model
- Trading at premium to sector average PB of -0.33
TRANSPACT vs Healthcare Peers — P/B Ratio Comparison
Transpact Enterprises P/B 17.13 vs Healthcare average -0.33, median 0.63 — range -17.92–1.01.
Sector Average
-0.33
Sector Median
0.63
Lowest P/B
-17.92
Highest P/B
1.01
Companies
50
| Company | Symbol | P/B Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Rekvina Laboratories | VINRKLB | -17.92 | ₹22 | Low |
| Span Divergent | SDL | -6.32 | ₹19 | Low |
| Oxygenta Pharmaceutical | OXYGENTAPH | -5.54 | ₹203 | Low |
| Satiate Agri | SATAGRI | -3.39 | ₹8 | Low |
| Adline Chem Lab | ADLINE | -3.03 | ₹5 | Low |
| Parmax Pharma | PARMAX | -2.48 | ₹14 | Low |
| Bharat Immunologicals | BIBCL | -2.32 | ₹76 | Low |
| Krebs Biochemicals & Ind… | KREBSBIO | -0.71 | ₹127 | Low |
| Cresanto Global | CRESANTO | -0.7 | ₹2 | Low |
| Vivimed Labs | VIVIMEDLAB | -0.63 | ₹53 | Low |